Elevance Health Holds Near $400 Following Q2 Earnings Beat

Key Facts

In a move reflecting the resilience of the managed healthcare sector, Elevance Health reported strong financial results for the second quarter of 2026. The company achieved revenue of $49.83 billion, exceeding analyst expectations, while earnings per share reached $7.45, significantly outperforming consensus estimates. Consequently, the company reaffirmed its full-year earnings guidance, signaling management's confidence in its trajectory despite a modest contraction in medical membership.

Per market data, ELV stock stood at $400.54 at the close of August 21, 2026, with daily trading ranging between a low of $396.96 and a high of $404.49. These movements occur as reports highlight the company's stable revenue base and a return on equity of 14.64%, supporting its investment case. Data also indicates the continuation of a quarterly dividend of $1.72 per share, bolstering cash returns for shareholders amid stable net profit margins of 2.47%.

Investors should watch current support levels as ELV closed at $400.54 (close August 21, 2026), near its recent price averages. Looking at the economic calendar, there are no immediate upcoming catalysts specifically for the healthcare sector in the next few days; however, broader sentiment may be influenced by recent US industrial production and housing data. Focus remains on the company's ability to sustain its medical membership base, which ended the quarter at 44.95 million members.